8-K: CytoDyn Raises $18.8M in Equity, Warrants

CytoDyn Inc. announced multiple unregistered sales of equity securities and warrants, raising approximately $18.8 million in cash and converting $1.5 million in debt to equity.

Summary

• CytoDyn Inc. completed a private offering to accredited investors through a placement agent, raising approximately $17.5 million in cash by selling 81.4 million units, each consisting of one common stock share and one warrant.
• The purchase price per unit was $0.2153, which was 90% of the lower of the intraday volume weighted average prices on January 30, 2026, and February 27, 2026.
• Warrants issued to investors have a five-year term and an exercise price of $0.26 per share, fully exercisable upon issuance.
• The company paid the placement agent a 13% cash fee of the gross proceeds and issued warrants to purchase approximately 12.2 million shares of common stock at an exercise price of $0.2153, exercisable for 10 years with a cashless exercise provision.
• Additionally, the placement agent has the right to exchange warrants for up to 3.0 million shares at the deal price.
• In direct private sales, CytoDyn issued 3,944,773 shares for approximately $1.0 million cash on January 23, 2026, and accepted a $100,000 investment on February 26, 2026, for 464,468 units under terms identical to the placement agent offering.
• Under a Standby Equity Purchase Agreement (SEPA) with Yorkville, the company sold approximately 0.8 million shares for $0.2 million cash in January 2026.
• In January and February 2026, the company converted approximately $1.5 million in convertible promissory notes into approximately 5.9 million shares of common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a necessary but highly dilutive capital raise, reflecting ongoing funding requirements and potentially challenging market conditions for the company, which could exert downward pressure on the stock.

Positives

• Successfully raised approximately $18.8 million in cash through various equity sales, providing capital for operations.
• Converted approximately $1.5 million of convertible debt into equity, reducing outstanding liabilities.

Negatives

• Significant dilution of existing shareholders due to the issuance of approximately 92.5 million new shares and warrants to purchase an additional 97.5 million shares (81.4M investor warrants + 0.46M investor warrants + 12.2M placement agent warrants + 3.0M exchangeable placement agent warrants).
• The unit purchase price of $0.2153 was at a 10% discount to the lower of the intraday volume weighted average prices, indicating a need to incentivize investors.
• A high cash fee of 13% of gross proceeds was paid to the placement agent, reducing net capital raised.
• Additional warrants were issued to the placement agent, creating further potential dilution.

Risks

• Dilution of existing shareholders' equity and voting power due to the substantial issuance of new common stock and warrants.
• Potential downward pressure on the stock price from the future exercise of warrants and the resale of shares covered by the planned registration statement.

Future Outlook

The company has agreed to use commercially reasonable efforts to prepare and file, and cause the SEC to declare effective, a registration statement under the Securities Act of 1933, as amended, covering the resale of the shares of common stock and the shares to be received upon the exercise of the warrants sold in the private placement.

Industry Context

StockSavvy.ai notes that capital raises via private placements, often involving units of common stock and warrants, and convertible debt conversions are common financing mechanisms for development-stage biotechnology companies like CytoDyn. These methods typically indicate a need for funding for ongoing research and development, clinical trials, or general operational expenses. The terms, including discounted pricing and significant warrant issuance, reflect the company's funding requirements and the prevailing market conditions for securing capital.

Comparison to Industry Standards

• StockSavvy.ai observes that the 13% placement agent fee and the issuance of warrants at a discount to the deal price are on the higher end for capital raises, particularly for development-stage biotechnology companies. This suggests a potentially challenging fundraising environment or a higher perceived risk profile compared to more established or clinically advanced peers.
• The discounted unit price of $0.2153, representing 90% of the lower volume-weighted average price, is indicative of a need to incentivize investors, which is common in challenging funding environments but can be less favorable than terms secured by companies with stronger market positions or more advanced product pipelines.

Stakeholder Impact

• Shareholders will experience significant dilution of their ownership percentage and potential downward pressure on share price due to the issuance of new shares and warrants, and the future resale of registered shares.

Next Steps

• Prepare and file a registration statement with the SEC covering the resale of the common stock and shares issuable upon warrant exercise from the private placement.

Key Dates

Recommendation

The substantial dilution from the private placement, direct sales, and convertible note exchanges, coupled with discounted pricing and significant warrant issuance, suggests considerable downward pressure on the stock. The high placement agent fees further reduce net proceeds. Investors face immediate dilution and the prospect of further dilution as warrants are exercised and registered shares are resold, making the stock a 'sell' for risk-averse investors.

Keywords

CytoDyn, CYDY, Equity Raise, Private Placement, Warrants, Convertible Notes, Dilution, SEC Filing, 8-K, Capital Raise, Biotechnology